Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085172 · ClinicalTrials.gov registry record · Phase 4
A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 4 study, sponsored by Shire.
- Completed
- Registry status
- Phase 4
- Development phase
- 396
- Enrollment target
NCT04085172 is a Phase 4 study that has completed, run by Shire. The registered enrollment target is 396 participants.
The verdict
NCT04085172, a Phase 4 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 396 participants
- Enrollment target
Study Summary
The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tablets.
Interventions
- OTHER Placebo
- DRUG Atomoxetine hydrochloride
- DRUG Guanfacine hydrochloride (TAK-503)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2019-09-18 |
| Est. Completion | 2025-09-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085172
The ClinicalTrials.gov registry entry for NCT04085172 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04085172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04085172 about?
NCT04085172 is a clinical study titled "A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)". The main aim of this study is learn more about long-term TAK-503 treatment in children and teenagers with ADHD for whom earlier stimulant treatment did not work. The study has two parts (A and B). In Part A, participants will take tablets of TAK-503, atomoxetine or placebo and in Part B TAK-503 tab...
What is the current status of trial NCT04085172?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 396 participants. The study started on 2019-09-18. Estimated completion is 2025-09-02.
What interventions are being tested in trial NCT04085172?
The interventions under investigation include: Placebo (OTHER), Atomoxetine hydrochloride (DRUG), Guanfacine hydrochloride (TAK-503) (DRUG).
Who is sponsoring clinical trial NCT04085172?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.